Indications for BAQSIMI:

Severe hypoglycemia.

Adults and Children:

<4yrs: not established. ≥4yrs: 3mg as single spray intranasally into one nostril. May repeat with new device after 15mins if no response. The dose does not require inhalation.


Pheochromocytoma. Insulinoma.


Increased blood pressure. Previously undiagnosed pheochromocytoma. Lack of efficacy in insulinoma; may cause hypoglycemia. Insufficient hepatic glycogen stores (eg, starvation, adrenal insufficiency, chronic hypoglycemia); treat with glucose. Pregnancy. Nursing mothers.

Pharmacologic Class:



Transient increase in pulse and blood pressure may occur with beta-blockers. Loss of efficacy or may produce hypoglycemia with indomethacin. May potentiate the anticoagulant effect of warfarin.

Adverse Reactions:

Nausea, headache, vomiting, upper respiratory tract irritation (eg, rhinorrhea, nasal discomfort/congestion, cough, epistaxis), watery eyes, redness of eyes, itchy nose/throat/eyes; allergic reactions.

Generic Availability:


How Supplied:

Pack—1, 2

Pricing for BAQSIMI

1 intranasal device of 3mg carton (Qty: 1)
Appx. price $296